The webinar "Economics of Establishing a Proton Therapy Center," will help educate hospitals and oncology centers about the economics of building a proton therapy center and how it can potentially expand oncology services. IBA will take the mystery out of establishing a proton therapy center by walking attendees through the cost, staff, ROI and reimbursement management for a proton therapy center.
The webinar takes place Thursday, Nov. 3, 2016, 2-3 p.m. Eastern Time
Joy Godby, BA, ROCC
Associate Director for Radiation Oncology
University of Texas MD Anderson Cancer Center
Godby manages the entire revenue cycle for radiation oncology (billing, coding, patient access, financial counseling, upfront appeals and back end appeals for all modalities). Her talk "Managing the Maze of Insurance authorization for Radiation Therapy" includes insights to reimbursement for oncology services.
Robert McElearney MBA
Vice President Strategic Accounts
IBA Proton Therapy North America
McElearney’s background in healthcare spans almost 20 years, working in every part of the country in senior positions of leadership in the healthcare industry. He led business development for the nation’s largest provider of mobile imaging services, directing its effort to expand into new business areas. McElearney provides overall new business leadership for IBA Inc. in partnering with health facilitates in developing a Proton Therapy Center.
Mary Elizabeth (Beth) Klein,
President, IBA Proton Therapy North America
Klein joined IBA in 2009, after more than 25 years with GE Healthcare. There she held various leadership roles including leading the nuclear medicine business and was the Americas commercial executive at TomoTherapy 2005-2007.
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer.s. The company is the worldwide technology leader in the field of proton therapy, which is considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single-room systems. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.
Headquartered in Belgium and employing about 1300 people worldwide, IBA has installed systems across the world. IBA is listed on the Pan-European stock exchange NYSE EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) More information can be found at: www.iba-worldwide.com